Traws Pharma advances clinical candidates to treat deadly hantavirus infections.

Traws Pharma announced plans to develop clinical candidates targeting hantavirus infections, a serious rodent-borne virus with a high fatality rate. The company leverages its antiviral drug portfolio, already active against similar RNA viruses like influenza and COVID-19, to quickly identify effective treatments. There are currently no approved therapies for hantavirus pulmonary disease, making this development critical amid recent outbreaks. Traws aims to expedite drug development and stockpile treatments for emergency use and national security.